Back to top

Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M

“During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Theravance Biopharma, Inc. (TBPH)